Eli Lilly Statistics
Total Valuation
Eli Lilly has a market cap or net worth of $869.41 billion. The enterprise value is $907.05 billion.
| Market Cap | 869.41B |
| Enterprise Value | 907.05B |
Important Dates
The last earnings date was Thursday, April 30, 2026, before market open.
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | May 15, 2026 |
Share Statistics
Eli Lilly has 891.74 million shares outstanding. The number of shares has decreased by -0.57% in one year.
| Current Share Class | 891.74M |
| Shares Outstanding | 891.74M |
| Shares Change (YoY) | -0.57% |
| Shares Change (QoQ) | -0.23% |
| Owned by Insiders (%) | 0.17% |
| Owned by Institutions (%) | 89.91% |
| Float | 889.35M |
Valuation Ratios
The trailing PE ratio is 34.63 and the forward PE ratio is 26.36. Eli Lilly's PEG ratio is 1.22.
| PE Ratio | 34.63 |
| Forward PE | 26.36 |
| PS Ratio | 12.03 |
| Forward PS | 9.97 |
| PB Ratio | 27.92 |
| P/TBV Ratio | 49.14 |
| P/FCF Ratio | 73.54 |
| P/OCF Ratio | 42.45 |
| PEG Ratio | 1.22 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 25.05, with an EV/FCF ratio of 76.72.
| EV / Earnings | 35.88 |
| EV / Sales | 12.55 |
| EV / EBITDA | 25.05 |
| EV / EBIT | 26.54 |
| EV / FCF | 76.72 |
Financial Position
The company has a current ratio of 1.50, with a Debt / Equity ratio of 1.39.
| Current Ratio | 1.50 |
| Quick Ratio | 0.72 |
| Debt / Equity | 1.39 |
| Debt / EBITDA | 1.19 |
| Debt / FCF | 3.67 |
| Interest Coverage | 388.32 |
Financial Efficiency
Return on equity (ROE) is 107.46% and return on invested capital (ROIC) is 41.92%.
| Return on Equity (ROE) | 107.46% |
| Return on Assets (ROA) | 20.74% |
| Return on Invested Capital (ROIC) | 41.92% |
| Return on Capital Employed (ROCE) | 42.75% |
| Weighted Average Cost of Capital (WACC) | 6.58% |
| Revenue Per Employee | $1.44M |
| Profits Per Employee | $505,540 |
| Employee Count | 50,000 |
| Asset Turnover | 0.70 |
| Inventory Turnover | 1.04 |
Taxes
In the past 12 months, Eli Lilly has paid $5.85 billion in taxes.
| Income Tax | 5.85B |
| Effective Tax Rate | 18.79% |
Stock Price Statistics
The stock price has increased by +25.78% in the last 52 weeks. The beta is 0.48, so Eli Lilly's price volatility has been lower than the market average.
| Beta (5Y) | 0.48 |
| 52-Week Price Change | +25.78% |
| 50-Day Moving Average | 943.25 |
| 200-Day Moving Average | 915.57 |
| Relative Strength Index (RSI) | 58.35 |
| Average Volume (20 Days) | 3,350,246 |
Short Selling Information
The latest short interest is 8.11 million, so 0.91% of the outstanding shares have been sold short.
| Short Interest | 8.11M |
| Short Previous Month | 6.87M |
| Short % of Shares Out | 0.91% |
| Short % of Float | 0.91% |
| Short Ratio (days to cover) | 2.70 |
Income Statement
In the last 12 months, Eli Lilly had revenue of $72.25 billion and earned $25.28 billion in profits. Earnings per share was $28.15.
| Revenue | 72.25B |
| Gross Profit | 59.85B |
| Operating Income | 34.17B |
| Pretax Income | 31.13B |
| Net Income | 25.28B |
| EBITDA | 36.22B |
| EBIT | 34.17B |
| Earnings Per Share (EPS) | $28.15 |
Balance Sheet
The company has $5.28 billion in cash and $43.37 billion in debt, with a net cash position of -$37.64 billion or -$42.21 per share.
| Cash & Cash Equivalents | 5.28B |
| Total Debt | 43.37B |
| Net Cash | -37.64B |
| Net Cash Per Share | -$42.21 |
| Equity (Book Value) | 31.20B |
| Book Value Per Share | 34.92 |
| Working Capital | 18.20B |
Cash Flow
In the last 12 months, operating cash flow was $20.48 billion and capital expenditures -$8.66 billion, giving a free cash flow of $11.82 billion.
| Operating Cash Flow | 20.48B |
| Capital Expenditures | -8.66B |
| Depreciation & Amortization | 2.04B |
| Net Borrowing | 4.46B |
| Free Cash Flow | 11.82B |
| FCF Per Share | $13.26 |
Margins
Gross margin is 82.83%, with operating and profit margins of 47.30% and 34.99%.
| Gross Margin | 82.83% |
| Operating Margin | 47.30% |
| Pretax Margin | 43.08% |
| Profit Margin | 34.99% |
| EBITDA Margin | 50.13% |
| EBIT Margin | 47.30% |
| FCF Margin | 16.36% |
Dividends & Yields
This stock pays an annual dividend of $6.92, which amounts to a dividend yield of 0.71%.
| Dividend Per Share | $6.92 |
| Dividend Yield | 0.71% |
| Dividend Growth (YoY) | 15.36% |
| Years of Dividend Growth | 11 |
| Payout Ratio | 22.95% |
| Buyback Yield | 0.57% |
| Shareholder Yield | 1.28% |
| Earnings Yield | 2.91% |
| FCF Yield | 1.36% |
Analyst Forecast
The average price target for Eli Lilly is $1,227.90, which is 25.94% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $1,227.90 |
| Price Target Difference | 25.94% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 20 |
| Revenue Growth Forecast (5Y) | 11.18% |
| EPS Growth Forecast (5Y) | 16.17% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on October 16, 1997. It was a forward split with a ratio of 2:1.
| Last Split Date | Oct 16, 1997 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Eli Lilly has an Altman Z-Score of 7.62 and a Piotroski F-Score of 6.
| Altman Z-Score | 7.62 |
| Piotroski F-Score | 6 |